RAS mutation is the most frequent oncogenic alteration in human cancers. KRAS is the most
frequently mutated followed by NRAS. The emblematic KRAS mutant cancers are …

A number of studies have shown that although antiepidermal growth factor receptor (EGFR)
monoclonal antibodies are effective treatments for metastatic colorectal cancer (mCRC) …

Evidence that activating mutations of the KRAS oncogene abolish the response to anti-
epidermal growth factor receptor therapy has revolutionized the treatment of advanced …

Mutations in RAS proteins occur widely in human cancer. Prompted by the confirmation of
KRAS mutation as a predictive biomarker of response to epidermal growth factor receptor …

KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly
associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is …

KRAS mutations have clearly emerged as a pharmacogenomic marker that can predict
which metastatic colorectal cancers will be resistant to treatment with antibodies that inhibit …

Mutations in codons 12 and 13 of the KRAS oncogene are relatively common in colorectal
and lung adenocarcinomas. Recent data indicate that these mutations result in resistance to …

Because of the current controversy on the origin and clinical value of circulating KRAS
codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction …

Both benign and malignant tumors represent heterogenous tissue containing tumor cells
and non-neoplastic mesenchymal and inflammatory cells. To detect a minority of mutant …

Adenocarcinomas of the lung remain a significant public health problem. Locally defined
(stage I) tumors are considered amenable to resection with curative intent. However, only …